Wall Street Zen Downgrades Outset Medical (NASDAQ:OM) to Sell

Outset Medical (NASDAQ:OM) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

A number of other research firms have also weighed in on OM. Stifel Nicolaus reduced their price objective on Outset Medical from $14.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, January 7th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $7.00 target price on shares of Outset Medical in a report on Wednesday, December 17th. BTIG Research reiterated a “buy” rating and set a $17.00 price target on shares of Outset Medical in a research report on Tuesday, December 16th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Outset Medical in a report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $10.67.

Outset Medical Stock Down 2.4%

NASDAQ:OM opened at $4.56 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 7.09 and a quick ratio of 5.77. The company’s fifty day moving average price is $5.21 and its 200-day moving average price is $11.81. Outset Medical has a 1-year low of $3.10 and a 1-year high of $21.98. The firm has a market capitalization of $82.76 million, a P/E ratio of -0.35 and a beta of 2.07.

Institutional Trading of Outset Medical

Institutional investors have recently bought and sold shares of the business. Legal & General Group Plc purchased a new stake in shares of Outset Medical in the second quarter valued at approximately $34,000. Ameritas Investment Partners Inc. purchased a new position in shares of Outset Medical during the 2nd quarter valued at approximately $35,000. BNP Paribas Financial Markets grew its stake in Outset Medical by 7,013.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after acquiring an additional 2,034 shares during the period. Police & Firemen s Retirement System of New Jersey purchased a new stake in Outset Medical in the 2nd quarter worth $78,000. Finally, New York State Common Retirement Fund purchased a new stake in Outset Medical in the 2nd quarter worth $108,000.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.